Search Results for "Cancer Diagnostics"

09:15 EDT 25th August 2016 | BioPortfolio

Matching Channels

Matching News

Quest Diagnostics introduces three new cancer test services

Quest Diagnostics has introduced three new cancer test services, which will enable clinicians to predict the development of hereditary forms of cancer in individuals.

Best of INVEST: Breath Diagnostics detects cancer with breath tests

Louisville startup Breath Diagnostics has developed technology to pick up cancer-related compounds that are exhaled in one’s breath.

AccuraGen, a US-China Cancer Diagnostics Company, Raises $40 Million

AccuraGen Holdings, a US-China cancer diagnostics company, has closed a $40 million Series B financing. AccuraGen develops blood tests that sequence cell free DNA (cfDNA) to provide sensitive and accu...

Cost-effective diagnostics for cancer? Only with VolitionRx!

Aberdeen, we say goodbye to you! We’re leaving Scotland this week and are heading down to Belgium. Besides being the place where most of the European Union action happens, Belgium also has a st...

Interpace Diagnostics introduces new pancreatic cancer testing product

Interpace Diagnostics Group has introduced a new version of its AccuCEA product dubbed Insights for pancreatic cancer testing.

What about PDL-1 in oncotherapy diagnostics for NSCLC?

What about PDL-1 in oncotherapy diagnostics for NSCLC? Larry H. Bernstein, MD, FCAP, Curator LPBI   Questions on PD-L1 Diagnostics for Immunotherapy in NSCLC Alexander M. Castellino, PhD http://w...

Quest Diagnostics to offer Biocept's lung cancer test in Mexico

Quest Diagnostics has agreed to make available Biocept's Target Selector mutation detection test for lung cancer in Mexico fo -More- 

A step forward in diagnostics

A step forward in diagnostics Larry H. Bernstein, MD, FCAP, Curator LPBI   3D Imaging of Cancer Cells Could Lead to Improved Ability of Pathologists and Radiologists to Plan Cancer Treatments and...

Matching PubMed Articles

Progress and potential of RAS mutation detection for diagnostics and companion diagnostics.

The importance of RAS mutation in carcinogenesis is established, and knowledge of an individual cancer's mutation status is important for optimal treatment.

Single-cell proteomics: potential implications for cancer diagnostics.

Single-cell proteomics in cancer is evolving and promises to provide more accurate diagnoses based on detailed molecular features of cells within tumors. This review focuses on technologies that allow...

Drug sensitivity testing platforms for gastric cancer diagnostics.

Gastric cancer diagnostics has traditionally been histomorphological and primarily the domain of surgical pathologists. Although there is an increasing usage of molecular and genomic techniques for cl...

Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer.

Companion diagnostics (CDx) have become a major tool in molecular pathology and assist in therapy decisions in an increasing number of various cancers. Particularly, the developments in lung cancer ha...

Activin A as a novel biomarker for colorectal adenocarcinoma in humans.

Early diagnostics of colorectal cancer is complicated by the lack of reliable serum biomarkers. This study aimed to investigate if the serum level of activin A can be used for diagnostics of this dise...

Search Whole site using Google

Quick Search
Advertisement Advertisement